Preview

Кардиология

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Роль возраста, сопутствующих заболеваний и активности ренин-ангиотензин-альдостероновой системы в проявлениях COVID-19. Эффекты ингибиторов АПФ и блокаторов ангиотензиновых рецепторов

https://doi.org/10.18087/cardio.2020.4.n1122

Полный текст:

Аннотация

В обзоре разбираются связь между коронавирусной болезнью 2019 (COVID-19) и функционированием ренин-ангиотензин-альдостероновой системы, а также причины неблагоприятного прогноза в зависимости от возраста больных и сопутствующих заболеваний. Подробно обсуждается возможное влияние ингибиторов ангиотензин превращающего фермента и антагонистов рецепторов к ангиотензину II первого типа на риск заражения и течения инфекции COVID-19 и влияние вируса SARS-COV-2 на сердечно-сосудистую систему.

Об авторах

Ю. В. Мареев
Национальный медицинский исследовательский центр терапии и профилактической медицины
Россия


В. Ю. Мареев
Mедицинский научно-образовательный центр МГУ им. М.В. Ломоносова, Москва
Россия

Доктор медицинских наук, профессор

Главный научный сотрудник Медицинского научно-образовательного центра МГУ имени М.В.Ломоносова

Член правления Общества Специалистов по Сердечной Недостаточности



Список литературы

1. Lakatta EG, Levy D. Arterial and Cardiac Aging: Major Shareholders in Cardiovascular Disease Enterprises: Part II: The Aging Heart in Health: Links to Heart Disease. Circulation. 2003;107(2):346–54. DOI: 10.1161/01.CIR.0000048893.62841.F7

2. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nature Medicine. 2005;11(8):875–9. DOI: 10.1038/nm1267

3. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-280.e8. DOI: 10.1016/j.cell.2020.02.052

4. Lakatta EG. The reality of getting old. Nature Reviews Cardiology. 2018;15(9):499–500. DOI: 10.1038/s41569-018-0068-y

5. Belenkov Yu.N., Mareev V.Yu. Principles of rational treatment of chronic heart failure. -M.: Media Medika;2000. – 266 p. [Russian: Беленков Ю.Н., Мареев В.Ю. Принципы рационального лечения хронической сердечной недостаточности. -М.: Медиа Медика; 2000. – 266с]

6. Skvortsov А.А., Nasonova S.N., Sychev A.V., Arbolishvili G.N., Baklanova N.A., Mareev V.Yu. et al. Combined therapy with quinapril, an ace inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect of monotherapy (data from the trial SADKO-CHF). Therapeutic Archive. 2005;77(8):34–43. [Russian: Скворцов А.А., Насонова С.Н., Сычев А.В., Арболишвили Г.Н., Бакланова Н.А., Мареев В.Ю. и др. Комбинированное применение ингибитора ангиотензинпревращающего фермента квинаприла и блокатора рецепторов 1-го типа к ангиотензину II валсартана у больных с умеренной хронической сердечной недостаточностью: возможно ли повышение степени нейрогормональной блокады и улучшение параметров суточной вариабельности ритма сердца по сравнению с действием монотерапии (по результатам исследования САДКО-ХСН). Терапевтический архив. 2005;77(8):34-43]

7. AlGhatrif M, Cingolani O, Lakatta EG. The Dilemma of Coronavirus Disease 2019, Aging, and Cardiovascular Disease: Insights from Cardiovascular Aging Science. JAMA Cardiology. 2020; [Epub ahead of print]. DOI: 10.1001/jamacardio.2020.1329

8. Arnold AC, Gallagher PE, Diz DI. Brain renin–angiotensin system in the nexus of hypertension and aging. Hypertension Research. 2013;36(1):5–13. DOI: 10.1038/hr.2012.161

9. Xudong X, Junzhu C, Xingxiang W, Furong Z, Yanrong L. Age- and gender-related difference of ACE2 expression in rat lung. Life Sciences. 2006;78(19):2166–71. DOI: 10.1016/j.lfs.2005.09.038

10. Schouten LR, van Kaam AH, Kohse F, Veltkamp F, Bos LD, de Beer FM et al. Age-dependent differences in pulmonary host responses in ARDS: a prospective observational cohort study. Annals of Intensive Care. 2019;9(1):55. DOI: 10.1186/s13613-019-0529-4

11. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Science China Life Sciences. 2020;63(3):364–74. DOI: 10.1007/s11427-020-1643-8

12. Liang W, Zhu Z, Guo J, Liu Z, He X, Zhou W et al. Severe Acute Respiratory Syndrome, Beijing, 2003. Emerging Infectious Diseases. 2004;10(1):25–31. DOI: 10.3201/eid1001.030553

13. Backhaus A. Coronavirus: Why it’s so deadly in Italy. Medium. 2020; [Internet. Av. at: https://medium.com/@andreasbackhausab/coronavirus-why-its-so-deadly-in-italy-c4200a15a7bf]

14. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A et al. Baseline Characteristics and Outcomes of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020; [Epub ahead of print]. DOI: 10.1001/jama.2020.5394

15. Official website of the Mayor of Moscow. Coronavirus: official information. Av. at: https://www.mos.ru/city/projects/covid-19/. 2020. [Russian: Официальный сайт Мэра Москвы. Коронавирус: официальная информация. Доступно на: https://www.mos.ru/city/projects/covid-19/. 2020.]

16. China: age distribution of novel coronavirus patients 2020. [Internet] Available at: https://www.statista.com/statistics/1095024/china-age-distribution-of-wuhan-coronavirus-covid-19-patients/

17. Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239. DOI: 10.1001/jama.2020.2648

18. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395(10229):1054–62. DOI: 10.1016/S0140-6736(20)30566-3

19. Watkins J. Re: Preventing a covid-19 pandemic: ACE inhibitors as a potential risk factor for fatal Covid-19. BMJ. 2020;m810. [Av. at: https://www.bmj.com/content/368/bmj.m810/rr-2]. DOI: 10.1136/bmj.m810

20. Phadke MA. Use of angiotensin receptor blockers such as Telmisartan, Losartsan in nCoV Wuhan Corona Virus infections – Novel mode of treatment. BMJ. 2020; [Av. at: https://www.bmj.com/content/368/bmj.m406/rr-2]

21. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. New England Journal of Medicine. 2020;NEJMsr2005760. [Epub ahead of print]. DOI: 10.1056/NEJMsr2005760

22. Roca-Ho H, Riera M, Palau V, Pascual J, Soler M. Characterization of ACE and ACE2 Expression within Different Organs of the NOD Mouse. International Journal of Molecular Sciences. 2017;18(3):563. DOI: 10.3390/ijms18030563

23. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA et al. Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2. Circulation. 2005;111(20):2605–10. DOI: 10.1161/CIRCULATIONAHA.104.510461

24. Ocaranza MP, Godoy I, Jalil JE, Varas M, Collantes P, Pinto M et al. Enalapril Attenuates Downregulation of Angiotensin-Converting Enzyme 2 in the Late Phase of Ventricular Dysfunction in Myocardial Infarcted Rat. Hypertension. 2006;48(4):572–8. DOI: 10.1161/01.HYP.0000237862.94083.45

25. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of Angiotensin-Converting Enzyme 2 After Myocardial Infarction by Blockade of Angiotensin II Receptors. Hypertension. 2004;43(5):970–6. DOI: 10.1161/01.HYP.0000124667.34652.1a

26. Hamming I, Van Goor H, Turner AJ, Rushworth CA, Michaud AA, Corvol P et al. Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats: Renal ACE and ACE2 during ACE inhibition and low salt. Experimental Physiology. 2008;93(5):631–8. DOI: 10.1113/expphysiol.2007.041855

27. Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK, Burrell LM. Combination renin–angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. Clinical Science. 2012;123(11):649–58. DOI: 10.1042/CS20120162

28. Furuhashi M, Moniwa N, Mita T, Fuseya T, Ishimura S, Ohno K et al. Urinary Angiotensin-Converting Enzyme 2 in Hypertensive Patients May Be Increased by Olmesartan, an Angiotensin II Receptor Blocker. American Journal of Hypertension. 2015;28(1):15–21. DOI: 10.1093/ajh/hpu086

29. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. International Journal of Oral Science. 2020;12(1):8. DOI: 10.1038/s41368-020-0074-x

30. Perico L, Benigni A, Remuzzi G. Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade. Nephron. 2020;1–9. [Epub ahead of print]. DOI: 10.1159/000507305

31. Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients with COVID-19. ClinicalTrials.gov Identifier: NCT04287686. 2020. [Av. at: https://clinicaltrials.gov/ct2/show/NCT04287686]

32. Guo J, Huang Z, Lin L, Lv J. Coronavirus Disease 2019 (COVID‐19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Journal of the American Heart Association. 2020;9(7):e016219. DOI: 10.1161/JAHA.120.016219

33. Zhang P, Zhu L, Cai J, Lei F, Qin J-J, Xie J et al. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients with Hypertension Hospitalized with COVID-19. Circulation Research. 2020; [Epub ahead of print]. DOI: 10.1161/CIRCRESAHA.120.317134

34. Bean D, Kraljevic Z, Searle T, Bendayan R, Pickles A, Folarin A et al. Treatment with ACE-inhibitors is associated with less severe disease with SARS-Covid-19 infection in a multi-site UK acute Hospital Trust. DOI: 10.1101/2020.04.07.20056788 [Av. at: http://medrxiv.org/lookup/doi/10.1101/2020.04.07.20056788]. 2020.

35. Liu Y, Huang F, Xu J, Yang P, Qin Y, Cao M et al. Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients. DOI: 10.1101/2020.03.20.20039586 [Av. at: http://medrxiv.org/lookup/doi/10.1101/2020.03.20.20039586]. 2020.

36. Yang G, Tan Z, Zhou L, Yang M, Peng L, Liu J et al. Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Usage is Associated with Improved Inflammatory Status and Clinical Outcomes in COVID-19 Patients with Hypertension. DOI: 10.1101/2020.03.31.20038935 [Av. at: http://medrxiv.org/lookup/doi/10.1101/2020.03.31.20038935]. 2020.

37. Losartan for Patients with COVID-19 Requiring Hospitalization. 2020. ClinicalTrials.gov Identifier: NCT04312009. [Internet] Available at: https://clinicaltrials.gov/ct2/show/NCT04312009

38. Losartan for Patients with COVID-19 Not Requiring Hospitalization. 2020. ClinicalTrials.gov Identifier: NCT04311177. [Internet] Available at: https://clinicaltrials.gov/ct2/show/NCT04311177

39. Caldeira D, Alarcao J, Vaz-Carneiro A, Costa J. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ. 2012;345:e4260–e4260. DOI: 10.1136/bmj.e4260

40. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–9. DOI: 10.1001/jama.2020.1585

41. Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovascular Research. 2020;cvaa078. [Epub ahead of print]. DOI: 10.1093/cvr/cvaa078

42. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiology. 2020; [Epub ahead of print]. DOI: 10.1001/jamacardio.2020.1286

43. Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin. European Heart Journal. 2020;ehaa190. [Epub ahead of print]. DOI: 10.1093/eurheartj/ehaa190

44. Guidelines for the diagnosis and treatment of diseases of the circulatory system (CCS) in the context of the COVID-19 pandemic. Av. at: https://scardio.ru/news/novosti_obschestva/rukovodstvo_po_diagnostike_i_lecheniyu_bolezney_sistemy_krovoobrascheniya_bsk_v_kontekste_pandemii_covid19/. 2020. [Russian: Руководство по диагностике и лечению болезней системы кровообращения (БСК) в контексте пандемии COVID-19. Доступно на: https://scardio.ru/news/novosti_obschestva/rukovodstvo_po_diagnostike_i_lecheniyu_bolezney_sistemy_krovoobrascheniya_bsk_v_kontekste_pandemii_covid19/. 2020]

45. Oudit GY, Kassiri Z, Jiang C, Liu PP, Poutanen SM, Penninger JM et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. European Journal of Clinical Investigation. 2009;39(7):618–25. DOI: 10.1111/j.1365-2362.2009.02153.x

46. De Simone G. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. Av. at: https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang. 2020.

47. American College of Cardiology. HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. Av. at: https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19. 2020.


Для цитирования:


Мареев Ю.В., Мареев В.Ю. Роль возраста, сопутствующих заболеваний и активности ренин-ангиотензин-альдостероновой системы в проявлениях COVID-19. Эффекты ингибиторов АПФ и блокаторов ангиотензиновых рецепторов. Кардиология. 2020;60(4):4-9. https://doi.org/10.18087/cardio.2020.4.n1122

For citation:


Mareev Y.V., Mareev V.Yu. Role of age, comorbidity and renin- angiotensin-aldosterone system in COVID-19. Effects of ACE inhibitors and angiotensin receptor blockers. Kardiologiia. 2020;60(4):4-9. (In Russ.) https://doi.org/10.18087/cardio.2020.4.n1122

Просмотров: 1486


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0022-9040 (Print)
ISSN 2412-5660 (Online)